ATGLin

ATGLin is a term used in the scientific literature to denote inhibitors of adipose triglyceride lipase (ATGL), the enzyme that catalyzes the initial step of triglyceride lipolysis by converting triglycerides into diacylglycerol and free fatty acids. The designation is not tied to a single, approved compound; rather, it refers to molecules that reduce ATGL activity in various research contexts. While Atglistatin is one of the better known ATGL inhibitors, ATGLin is not an official drug name and its use can vary between studies.

Mechanistically, ATGLin compounds are intended to decrease lipolysis in adipose tissue, thereby lowering the release of fatty acids into circulation. The resulting metabolic effects depend on the tissue, nutritional state, and degree of inhibition, and can influence energy homeostasis, insulin signaling, and lipid accumulation in non-adipose organs. In experimental settings, ATGLin inhibitors help delineate ATGL-dependent pathways and clarify the enzyme’s role in metabolic diseases.

Research and therapeutic considerations include variable specificity and pharmacokinetic properties among ATGLin compounds, as well as potential off-target effects. Chronic inhibition of ATGL can lead to lipid redistribution or accumulation in the liver and other tissues, with possible adverse consequences for energy balance. Because ATGLin is a class concept rather than a single approved drug, researchers typically cite the specific inhibitor used (for example, Atglistatin) when precision is required.

See also: adipose triglyceride lipase (ATGL), CGI-58 (ABHD5), lipolysis.